{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:15:16Z","timestamp":1715984116495},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T00:00:00Z","timestamp":1510099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>There is a scarcity of real\u2010world data on treatment patterns and outcomes among advanced melanoma patients treated with immunotherapies including ipilimumab, an anti\u2010CTLA\u20104 antibody approved since 2011.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate ipilimumab and postipilimumab treatment patterns and outcomes among patients with advanced melanoma in Australia, Germany, Italy and Spain, following regulatory approval.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective multicentre, multinational, observational chart review study. Data were extracted from the start of ipilimumab therapy until the end of at least 40\u00a0weeks of follow\u2010up, or death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data from 371 patients (Australia, 103; Germany, 152; Italy, 76; Spain, 40) were analysed. Mean age was 65\u00a0years; 62% were male. Eastern Cooperative Oncology Group performance status (ECOG PS) was 0 or 1 for 94%. In 67%, ipilimumab was initially received as second\u2010line or later therapy. Patients received on average 3.4 ipilimumab doses. The ipilimumab\u2010refractory cohort comprised of 226 patients. Of these, 17% in Australia, 47% in Germany, 29% in Italy and 14% in Spain received another antimelanoma treatment after ipilimumab including chemotherapy in 26% and BRAF\/other kinase inhibitors in 11%. Ipilimumab\u2010refractory patients who received postipilimumab treatment showed a 40% reduced hazard of dying than those not receiving treatment after ipilimumab (HR 0.60; 95% CI 0.43\u20130.83), after adjustment for potential confounders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>During the time observed, ipilimumab was mainly used as second\u2010line or later therapy. A significant proportion of patients received postipilimumab therapy, most of which was chemotherapy. Nevertheless, overall survival following progression on ipilimumab treatment remained poor, highlighting the need for research to develop more effective end\u2010of\u2010life treatment options.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.14633","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T13:08:40Z","timestamp":1508245720000},"page":"962-971","source":"Crossref","is-referenced-by-count":14,"title":["Real\u2010world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab"],"prefix":"10.1111","volume":"32","author":[{"given":"P.","family":"Mohr","sequence":"first","affiliation":[{"name":"Elbe\u2010Klinikum Buxtehude Buxtehude Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori Fondazione Pascale Naples Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Arance","sequence":"additional","affiliation":[{"name":"Hospital Clinic Barcelona Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"McArthur","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre East Melbourne Vic. Australia"},{"name":"University of Melbourne Parkville Vic. Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hernaez","sequence":"additional","affiliation":[{"name":"Mapi Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Kaskel","sequence":"additional","affiliation":[{"name":"MSD SHARP &amp; DOHME GMBH Haar Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Shinde","sequence":"additional","affiliation":[{"name":"Merck &amp; Co. Inc. Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Stevinson","sequence":"additional","affiliation":[{"name":"Merck &amp; Co. Inc. Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,11,8]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11","author":"Ferlay J","year":"2013"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2013.06.002"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.7837"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2013.0055"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0066"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds229"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv297"},{"issue":"6","key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ddg.12044","article-title":"Malignant melanoma S3\u2010guideline \u201cdiagnosis, therapy and follow\u2010up of melanoma\u201d","volume":"11","author":"Pflugfelder A","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja13.10448"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-116"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000108"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0716-5"},{"issue":"6","key":"e_1_2_8_16_1","first-page":"1106O","article-title":"Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg\/kg vs 10 mg\/kg in patients with metastatic melanoma (MEL)","volume":"27","author":"Ascierto PA","year":"2016","journal-title":"Annals of Oncology"},{"key":"e_1_2_8_17_1","unstructured":"Determina_Yervoy_15_09_2014 Agenzia farmaco Italy. URLhttp:\/\/www.agenziafarmaco.gov.it\/sites\/default\/files\/Determina_Yervoy_15_09_2014.pdf(last accessed: 01 March 2016)."},{"key":"e_1_2_8_18_1","unstructured":"Label Yervoy Australia. URLhttp:\/\/www.medicines.org.au\/files\/lprint\/bqcyervo-lp.pdf(last accessed: 01 March 2016)."},{"key":"e_1_2_8_19_1","unstructured":"SmPC Yervoy European Commission. URLhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002213\/WC500109299.pdf(last accessed: 01 March 2016)."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001050050149"},{"key":"e_1_2_8_21_1","first-page":"259","article-title":"Chemotherapy resistance abrogation in metastatic melanoma","volume":"8","author":"Tawbi HA","year":"2010","journal-title":"Clin Adv Hematol Oncol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14633","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T19:19:49Z","timestamp":1695496789000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,8]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1111\/jdv.14633"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14633","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,8]]}}}